Please login to the form below
Crohn's Disease
This page shows the latest Crohn's Disease news and features for those working in and with pharma, biotech and healthcare.
AbbVie lauds head-to-head win for Skyrizi versus Cosentyx
according to AbbVie outperformed its rival across all the trial’s primary and secondary outcome measures. ... It also has registration trials for Skyrizi ongoing in Crohn's disease and ulcerative colitis due to generate results next year, as well as
Latest news
-
Takeda’s subcutaneous Entyvio formulation faces FDA rejection
treatments. It also indicated for use in adult patients with moderate-to-severe active Crohn’s Disease who have similarly had inadequate responses to standard treatments. ... after a lead-in period, were in remission from the inflammatory bowel disease
-
PMEA 2019: Recognising excellence in improving patient outcomes
Taking home this award was Takeda and Uptake Strategies for ENTYVIO’s Brand Healing (see image below), which positively impacted thousands of Ulcerative Colitis and Crohn’s Disease patients across the ... The two winners of this impressive award were
-
Provention Bio wins PRIME designation for type 1 diabetes prevention drug
Stumble in Crohn’s study. On the flip-side, Provention also announced that one of its J&J partnered drugs has failed a mid-stage study. ... The drug was being studied in a phase 2a study in moderate-to-severe Crohn’s disease patients, with its
-
Janssen files Tremfya for psoriatic arthritis in Europe
indications like PsA, Crohn’s disease, and ulcerative colitis – to compensate. ... Lilly’s drug also outperformed AbbVie’s $20bn TNF inhibitor blockbuster Humira (adalimumab) in PsA in the SPIRIT trial reported this summer at the EULAR congress.
-
Takeda makes Crohn’s disease case for subcutaneous Entyvio
Hopes to aid growth. Takeda has new clinical data on a subcutaneous formulation of its Entyvio drug in Crohn’s disease, expanding the potential of the drug beyond ulcerative colitis. ... Top-line results from the VISIBLE 2 trial show the new
More from news
Approximately 20 fully matching, plus 149 partially matching documents found.
Latest Intelligence
-
Drug launches to watch in 2019
The first test of this will be Shire’s new blockbuster-in-waiting Takhzyro, which gained EMA approval in November, for the rare disease hereditary angioedema (HAE). ... Boehringer Ingelheim) for psoriatic arthritis, Crohn’s disease and other
-
Deal Watch October 2018
Collaboration for. development. $760m. Enterome/. Takeda. EB8018 for Crohn’s disease and other gastrointestinal. ... Roche has an existing agreement with Ionis for IONIS‐HTTRx, an antisense drug for Huntington’s Disease, and the new deal is to
-
Innovation in merger control and the impact on the pharmaceutical sector
Pipeline problems. The Commission’s novel approach has its roots in pharma mergers. ... Specifically, Hospira was selling Inflectra, an infliximab biosimilar used to treat several chronic inflammatory diseases, notably the inflammation of Crohn’s
-
Deal Watch January 2018
for local administration for the treatment of complex perianal fistulas in patients with Crohn’s disease. The companies were already partners having signed a $432m licensing deal in July 2016 for ... Option exercise (2 options). 640. TiGenix/Takeda.
-
The good, the bad and the ugly
Tecfidera (MS) and Spinraza (Spinal Muscular Atrophy) are expected to generate big sales, while Tysabril (MS and Crohn’s Disease) and Avonex (MS) are expected to see sales drop due to ... However, there is a movement towards greater research in this
More from intelligence
Approximately 0 fully matching, plus 22 partially matching documents found.
Latest appointments
-
TiGenix appoints Dr Marie Paule Richard
in phase III trials for complex perianal fistulas in Crohn's disease.
-
Ex J&J VP joins board of Immune
Immune will benefit from Durrant's knowledged of the iundstry gained during time in roles such as worldwide VP at Johnson &Johnson and VP, Pharmacia until its acquisition by Pfizer. ... Its lead product candidate is bertilimumab, which is in clinical
-
Former Novartis president joins Qu Biologics
His senior industry experience will support Qu Biologics' plans to advance the development of its investigational immunotherapies for treatments such as Crohn's disease. ... Bob Pelzer's wealth of leadership experience with Novartis and DuPont will be
More from appointments
Approximately 1 fully matching, plus 2 partially matching documents found.
Latest from PMHub
-
Cello Health Insight wins EphMRA’s 2019 Market Research Excellence Award for 'Business Impact through Innovation'
Cello Health Insight in partnership with Janssen Pharmaceuticals has won EphMRA’s 2019 Market Research Excellence Award for 'Business Impact through Innovation'. ... The winning entry focused on exploring the Crohn’s Disease and Ulcerative Colitis
-
The Real & The Honestly Fake
If the audience’s attention span has decreased, agencies and advertisers must grab what little attention there is. ... about how to deal with Duchenne, the depictions of dragons to represent the struggles of suffering with Crohn’s disease, the
-
emotive adds to medical team with new Scientific Lead and Associate Medical Writer
Kate is experienced in a wide range of therapy areas, including immunology, specifically Crohn’s disease, ulcerative colitis and psoriatic arthritis, in ophthalmology, including retinal diseases, glaucoma and dry eye disease, ... in rare
-
THE OTHER SIDE OF… CROHN’S DISEASE
Meet Irene. Like millions of others worldwide (and an estimated 115, 000 in the UK), Irene suffers from Crohn’s disease, an autoimmune disorder that causes inflammation in the gut and ... So she turns elsewhere for information. She speaks to other
-
Creativity in a complex landscape: a pharma perspective
For example, when developing messaging, it’s important to know what restrictions and barriers might come into play for different countries. ... An example of what I would consider an outstanding creative campaign is the ‘Rewrite Their Stories’
More from PMHub
Approximately 5 fully matching, plus 9 partially matching documents found.
Featured jobs
-
Account Director
-
£Competitive Salary
- Client Services Director - Digital MedComms
-
£60000 - £80000 per annum, Benefits: Pension, healthcare, dedicated training budget, regul
-
Senior External Communications Lead
-
£Competitive Salary
- Account Manager, Healthcare Communications
-
£32, 000 - £40, 000 bonus benefits
-
Account director
-
Competitive salary and bonus scheme
- Senior Medical Writer or Lead Medical Writer
-
£Competitive Salary
- Account Director, Healthcare Communications
-
Salary TBC
- Digital Associate Director - Medcomms
-
£65000 - £80000 per annum
-
Account Director, Medical Education
-
Salary TBC
-
Scientific Director
-
£60000 - £85000 per annum, Benefits: Bonus, pension, subsidised gym and much more
- Account Director, Medical Communications & Events
-
£50 - 65, 000 according to skills and experience benefits
-
Account Manager
-
£Competitive Salary
-
Publications director
-
Competitive salary and bonus scheme
- Senior Medical Writer, MedComms Agency
-
Salary TBC
- Brand Manager - Medium Global Pharma Company
-
£Competitive Financial Package
-
Account Manager (PR)
-
Great Benefits
Subscribe to our email news alerts
- J&J gets US backing for vaccine against coronavirus, christened Covid-19
- Genital herpes vaccine candidate heads for human studies
- It started with a miss
- Merck chases Roche with triple-negative breast cancer data for Keytruda
- A market-adapted agile approach to launch excellence
- CRISPR gene-editing in cancer patients is safe, according to new study
- AZ revenues rise, but it says coronavirus could hit 2020
- Seattle Genetics wins FDA priority review for oral HER2 drug
- Eisai agrees to pull obesity drug Belviq after safety alert
- FDA begins speedy review of BMS’ CAR-T liso-cel
- It’s Teenage Kicks for Lucid Group
- 20 for 2020 – Five pharma companies to watch
No results were found
PMHub
Market Access Transformation
Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...
Latest intelligence
- 20 for 2020 – Five pharma companies to watch
- As a new decade gets into gear, we take a look at five pharma companies that have a lot riding on 2020...
- The growing clinical importance of patient-reported outcomes (PROs)
- Traditionally, the success or otherwise of medical treatments has been assessed by mortality or clinical assessments of health. However, patient self-reports of health are increasingly seen as central to the...
- The roaring ‘20s and Generation Z
- How a new generation will shape pharma comms this decade...
Quick links
Infographics
